|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
/ Enrolling by invitation临床1期 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Food Effect of ND-003 Tablets in Healthy Adult Volunteers
The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults
评价ND-003片在健康成年志愿者中单、多次给药的安全性、耐受性、药代动力学特征以及食物影响的Ⅰ期临床研究
1、评估健康成年志愿者单次/多次口服ND-003片的安全性及耐受性。
2、评估健康成年志愿者单次/多次口服ND-003片的药代动力学特征。
3、评价食物对健康成年志愿者单次口服ND-003片药代动力学的影响。
/ Enrolling by invitation临床1期 A Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.
This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.
100 项与 深圳市小分子新药创新中心有限公司 相关的临床结果
0 项与 深圳市小分子新药创新中心有限公司 相关的专利(医药)
100 项与 深圳市小分子新药创新中心有限公司 相关的药物交易
100 项与 深圳市小分子新药创新中心有限公司 相关的转化医学